Trust Can't Boot Abbott's Humira Patent Challenge

Law360, New York (October 14, 2011, 4:32 PM EDT) -- A New York federal judge on Friday shot down a move by the Mathilda and Terence Kennedy Institute of Rheumatology Trust to dismiss Abbott Biotechnology Ltd.'s suit over the institute's patent allegedly covering the anti-inflammatory drug Humira.

Abbott, which produces and markets Humira, has a licensing agreement with Mathilda that allows Abbott to market the use of Humira in combination with the antimetabolite and antifolate drug methotrexate, the suit says. This drug cocktail is covered by Mathilda's U.S. Patent No. 6,270,766, according to the suit....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.